[go: up one dir, main page]

GT200900235A - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
GT200900235A
GT200900235A GT200900235A GT200900235A GT200900235A GT 200900235 A GT200900235 A GT 200900235A GT 200900235 A GT200900235 A GT 200900235A GT 200900235 A GT200900235 A GT 200900235A GT 200900235 A GT200900235 A GT 200900235A
Authority
GT
Guatemala
Prior art keywords
pharmaceutical compositions
compositions
calcilitico
osea
troubling
Prior art date
Application number
GT200900235A
Other languages
English (en)
Inventor
Buhl Thomas
Goncalves Elisabete
Kalb Oscar
Meinel Lorenz
Reidemeister Sibylle
Taillardat Agnes
Widler Leo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38016483&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200900235(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200900235A publication Critical patent/GT200900235A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS, EN PARTICULAR A COMPOSICIONES PARA LA ADMINISTRACION ORAL DE UN CALCILITICO COMO UN AGENTE ACTIVO DE UTILIDAD EN CUADROS DE OSTEOPOROSIS, LA CUAL SE CARACTERIZA POR UNA BAJA MASA OSEA Y POR EL DETERIORO MICRO-ARQUITECTONICO DEL TEJIDO OSEO, QUE CONDUCE A FRAGILIDAD Y A MAYOR RIESGO DE FRACTURAS.
GT200900235A 2007-03-02 2009-08-31 Composiciones farmaceuticas GT200900235A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07103365A EP1964548A1 (en) 2007-03-02 2007-03-02 Pharmaceutical compositions comprising a calcilytic agent

Publications (1)

Publication Number Publication Date
GT200900235A true GT200900235A (es) 2010-03-15

Family

ID=38016483

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900235A GT200900235A (es) 2007-03-02 2009-08-31 Composiciones farmaceuticas

Country Status (20)

Country Link
US (1) US20100022565A1 (es)
EP (2) EP1964548A1 (es)
JP (1) JP2010520179A (es)
KR (1) KR20090125245A (es)
CN (1) CN101621993A (es)
AR (1) AR065564A1 (es)
AU (1) AU2008223876A1 (es)
CA (1) CA2678794A1 (es)
CL (1) CL2008000617A1 (es)
CO (1) CO6210808A2 (es)
EC (1) ECSP099611A (es)
GT (1) GT200900235A (es)
IL (1) IL200274A0 (es)
MA (1) MA31201B1 (es)
MX (1) MX2009009343A (es)
PE (1) PE20081794A1 (es)
TN (1) TN2009000358A1 (es)
TW (1) TW200843762A (es)
WO (1) WO2008107390A1 (es)
ZA (1) ZA200905472B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606426D0 (en) * 2006-03-30 2006-05-10 Novartis Ag Benzimidazole derivatives
WO2008041118A2 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
US9073294B2 (en) 2013-06-04 2015-07-07 Monosol, Llc Method for sealing a water-soluble film by applying a sealing solution
US10857127B2 (en) * 2016-05-20 2020-12-08 Azure Biotech, Inc. Vaginal delivery systems containing selective estrogen receptor modulator (SERM) and uses thereof
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
KR102220255B1 (ko) * 2019-08-13 2021-02-26 동국대학교 산학협력단 수술 후 부갑상선기능저하증 개선 또는 치료용 약학 조성물 및 이를 이용한 치료 방법
WO2021029517A1 (en) * 2019-08-13 2021-02-18 Dongguk University Industry-Academic Cooperation Foundation Pharmaceutical composition for improving or treating post-surgical hypoparathyroidism and treatment method using the same
IL300285A (en) * 2020-08-04 2023-04-01 Calcilytix Therapeutics Inc Formulations of triphenyl calcilytic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202261B2 (en) * 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
PE20001456A1 (es) * 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
AU2003291761A1 (en) * 2002-11-04 2004-06-07 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics

Also Published As

Publication number Publication date
TW200843762A (en) 2008-11-16
EP1964548A1 (en) 2008-09-03
CO6210808A2 (es) 2010-10-20
IL200274A0 (en) 2010-04-29
JP2010520179A (ja) 2010-06-10
EP2124893A1 (en) 2009-12-02
WO2008107390A1 (en) 2008-09-12
MA31201B1 (fr) 2010-02-01
AU2008223876A1 (en) 2008-09-12
MX2009009343A (es) 2009-09-11
TN2009000358A1 (en) 2010-12-31
KR20090125245A (ko) 2009-12-04
US20100022565A1 (en) 2010-01-28
PE20081794A1 (es) 2009-01-09
CA2678794A1 (en) 2008-09-12
ECSP099611A (es) 2009-10-30
AR065564A1 (es) 2009-06-17
CL2008000617A1 (es) 2008-09-12
ZA200905472B (en) 2010-04-28
CN101621993A (zh) 2010-01-06

Similar Documents

Publication Publication Date Title
GT200900235A (es) Composiciones farmaceuticas
HN2011003011A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
MX2011011514A (es) Formulaciones de canabidiol y metodos para utilizarlas.
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
MX346861B (es) Metodos de tratamiento de carcinoma hepato celular.
UY28862A1 (es) Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
BRPI0925036B8 (pt) uso de trans-t-butil ciclo-hexanol, composição cosmética, medicamento, seus usos e processos para tratar irritação na pele
CO6670567A2 (es) Métodos de tratamiento contra el cáncer pancreático
AR070888A1 (es) Composiciones farmaceuticas con buena biodisponibilidad
MX2012005013A (es) Pterostilbeno (peter) para su uso en la prevencion y/el tratamiento de enfermedades, daños o lesiones de la piel.
UY31780A (es) Fenoxibenzamidas sustituidas
PE20121495A1 (es) Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta
TR200900878A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
AR081082A1 (es) Composiciones organicas para tratar enfermedades relacionadas con beta-enac
MX367091B (es) Una composición farmacéutica o cosmética tópica que comprende un extracto de la baya de la fruta milagrosa (synsepalum dulcificum) para usarse en el tratamiento o la prevención de desórdenes en la piel, mebrana mucosa, cabello, articulaciones y uñas.
UY32457A (es) Vacuna del virus del dengue inactivado
ECSP14013200A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
UY35848A (es) Tienopirimidinas
CO6551731A2 (es) Composiciòn de combinaciòn que comprende como ingrediente activo l- carnitina o propionil l- carnitina, para la prevenciòn o tratamiento de insuficienca venosa crònica
AR075274A1 (es) Agente de tratamiento de semillas y metodo para proteger una planta
TR200900879A2 (tr) Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
MX2016006006A (es) Metodo para el manejo del cancer y para el tratamiento de las comorbilidades relacionadas con el cancer.
BR112015011693A2 (pt) composições fibrinolíticas compreendendo bromelina e nattokinase para a prevenção e tratamento de estados flebotrombóticos
ES2531407T3 (es) Composiciones dermatológicas que contienen una asociación de lípidos peroxidados y zinc y sus utilizaciones particularmente en el tratamiento del herpes